EPISODE · Feb 23, 2026 · 44 MIN
From Signal to Cure: How AI is Ending the "Trial-and-Error" of Modern Medicine with Elaine Phan & Andreas Taylor
from GSD Venture Studios Podcasts by Gary Fowler · host GSD Venture Studios
In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor.We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan.Key Topics Covered:The shift from reactive medicine to AI-driven Precision Medicine.How "Continuous Patient Signals" improve subtyping and stratification.The role of AI in streamlining the lifecycle from drug discovery to post-market management.The future of longevity and bio-tech innovation.About the Guests:Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna.Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery.Connect with GSD Venture Studios: gsdvs.com#PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma
Embed this episode
NOW PLAYING
From Signal to Cure: How AI is Ending the "Trial-and-Error" of Modern Medicine with Elaine Phan & Andreas Taylor
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.